Literature DB >> 8175748

Complete primary structure of the sixth chain of human basement membrane collagen, alpha 6(IV). Isolation of the cDNAs for alpha 6(IV) and comparison with five other type IV collagen chains.

J Zhou1, M Ding, Z Zhao, S T Reeders.   

Abstract

Basement membranes were previously believed to contain five distinct type IV collagen subunits. We have recently isolated part of the cDNA for a novel type IV collagen, alpha 6(IV), and shown that COL4A6, the gene encoding this new chain, is deleted in Alport syndrome-associated leiomyomatosis (Zhou, J., Mochizuki, T., Smeets, H., Antignac, C., Laurila, P., de Paepe, A., Tryggvason, K., and Reeders, S. T. (1993) Science 261, 1167-1169). Here, we describe the entire human alpha 6(IV) cDNA and show that the gene encodes a classical type IV collagen with homology throughout its length to all the other five chains. There is a 21-residue signal peptide, a 1417-residue collagenous domain interrupted at 25 points, and a 228-residue carboxyl-terminal non-collagenous domain. When the complete primary structure of this new chain was compared with all the other known chains, it became clear that alpha 6(IV) has the most resemblance to alpha 2(IV) and alpha 4(IV). The evolution of the six chains was deduced, allowing a new classification of the type IV collagen family. The alpha 6(IV) chain is a candidate gene for X-linked Alport syndrome; knowledge of the complete structure of the chain will permit us to screen systematically for mutations in patients and to generate recombinant proteins and synthetic peptides for further study of cell-matrix interactions involving the alpha 6(IV) chain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175748

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Degradation of human collagen isoforms by Clostridium collagenase and the effects of degradation products on cell migration.

Authors:  Lei Shi; Ryan Ermis; Anastacia Garcia; Dale Telgenhoff; Duncan Aust
Journal:  Int Wound J       Date:  2010-04       Impact factor: 3.315

Review 2.  Type IV collagen-derived angiogenesis inhibitors.

Authors:  Thomas M Mundel; Raghu Kalluri
Journal:  Microvasc Res       Date:  2007-05-25       Impact factor: 3.514

3.  Somatic deletion of the 5' ends of both the COL4A5 and COL4A6 genes in a sporadic leiomyoma of the esophagus.

Authors:  L Heidet; E Boye; Y Cai; Y Sado; X Zhang; J F Fléjou; F Fékété; Y Ninomiya; M C Gubler; C Antignac
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

4.  Nephritogenicity and alpha-chain composition of NC1 fractions of type IV collagen from bovine renal basement membrane.

Authors:  S Rauf; M Kagawa; Y Kishiro; S Inoue; I Naito; T Oohashi; M Sugimoto; Y Ninomiya; Y Sado
Journal:  Virchows Arch       Date:  1996-07       Impact factor: 4.064

Review 5.  Interpreting cDNA sequences: some insights from studies on translation.

Authors:  M Kozak
Journal:  Mamm Genome       Date:  1996-08       Impact factor: 2.957

Review 6.  Extracellular matrix and the kidney.

Authors:  P N Furness
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

Review 7.  Minor collagens of the skin with not so minor functions.

Authors:  Georgios Theocharidis; John T Connelly
Journal:  J Anat       Date:  2017-02-02       Impact factor: 2.610

8.  Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys.

Authors:  L Heidet; Y Cai; L Guicharnaud; C Antignac; M C Gubler
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

9.  Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome.

Authors:  E Boye; G Mollet; L Forestier; L Cohen-Solal; L Heidet; P Cochat; J P Grünfeld; J B Palcoux; M C Gubler; C Antignac
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

10.  Developmental distribution of collagen IV isoforms and relevance to ocular diseases.

Authors:  Xiaoyang Bai; David J Dilworth; Yi-Chinn Weng; Douglas B Gould
Journal:  Matrix Biol       Date:  2009-03-09       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.